March 26, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel

Basel, 26 March 2018 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel These additional data will be submitted to health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines... Read more

March 22, 2018 Clinical Research/Diagn. PR/Corporate

Precipio Restructures Capitalization Table

INVESTORS TO CONVERT PREFERRED SHARES AND EXERCISE WARRANTS NEW HAVEN, Conn., March 22, 2018 (GLOBE NEWSWIRE) — Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), in an 8-K issued today announced an agreement with investors in certain 2017 underwritten and registered direct offerings, to convert their preferred shares and exercise a substantial portion of their warrants. The benefit to common stockholders... Read more

March 21, 2018 Environ, Ag./Food & Bev PR/Corporate

Neogen’s Listeria Right Now™ wins CFIA innovation award

CONTACT: Joanne McPeake, Neogen Europe Ltd., +44(0) 1292 525 600 AYR, Scotland, 21 March, 2018 — Neogen’s revolutionary Listeria Right Now™ environmental pathogen detection system has won a 2018 CFIA innovation trophy. The CFIA (Carrefour des Fournisseurs de l’Industrie Agroalimentaire) is an annual agro-food industry supplier fair held in France that showcases the latest developments in food industry technology.... Read more

March 20, 2018 Life Science Tools PR/Corporate

Oxford Nanopore announces £100 million ($140M) fundraising from global investors

Tue 20th March 2018 Funding will support new manufacturing facility, commercial expansion, and development of new innovative products. Oxford, UK. Oxford Nanopore Technologies Ltd, the company behind the only portable real-time DNA/RNA sequencer, MinION, has raised £100M ($140M) in new investment. Funds were raised from global investors including GIC (Singapore), CCB International (CCBI, China), Hostplus (Australia),... Read more

March 20, 2018 Informatics & Software PR/Corporate

ATL Announces Appointment of Steve Chase as Chief Executive Officer

March 20, 2018: Accelerated Technology Laboratories, Inc. (ATL), a leader in Laboratory Information Management Systems (LIMS), is pleased to announce that Steve Chase is joining the company as Chief Executive Officer (CEO). This appointment is effective immediately and concludes a search process conducted by ATL’s executive leadership team. As CEO, Steve will oversee ATL’s ambitious near... Read more

March 20, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer

Basel, 20 March 2018 Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its... Read more

March 20, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer

Basel, 20 March 2018 Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its... Read more

March 19, 2018 Clinical Research/Diagn. Informatics & Software Life Science Tools PR/Corporate

Human Longevity, Inc. Hires Former Ancestry Executive, Scott Sorensen, As New Chief Technology Officer

INDUSTRY LEADER BRINGS 25 YEARS OF EXPERTISE IN SOFTWARE PRODUCTS AND SERVICES TO HELP HLI SCALE BUSINESS SAN DIEGO, March 19, 2018 /PRNewswire/ — Human Longevity, Inc. (HLI) – the genomics-powered health intelligence company – announced today that Scott Sorensen is joining the leadership team as Chief Technology Officer, reporting to J. Craig Venter, Ph.D., Co-Founder, Chairman and CEO. Sorensen joins... Read more

March 19, 2018 Clinical Research/Diagn. Informatics & Software Life Science Tools PR/Corporate

Luna DNA Expands Leadership and Advisory Board, Adding New Pedigree From Illumina

Three industry leaders join company ranks to drive genomic discovery SAN DIEGO, March 19, 2018 /PRNewswire/ — 9:30 a.m. PT — Luna DNA, the first community owned genomic and medical research database, today announced the addition of three new members to its leadership team. The key hires in the VP of marketing and VP of business strategy and operation... Read more